Ballentine Partners’s Medtronic MDT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.06M | Sell |
13,573
-4,983
| -27% | -$402K | 0.01% | 356 |
|
|
2026
Q1 | $1.61M | Buy |
18,556
+3,069
| +20% | +$294K | 0.02% | 243 |
|
|
2025
Q4 | $1.49M | Buy |
15,487
+214
| +1% | +$20.8K | 0.02% | 245 |
|
|
2025
Q3 | $1.45M | Buy |
15,273
+1,427
| +10% | +$131K | 0.02% | 260 |
|
|
2025
Q2 | $1.21M | Sell |
13,846
-3,101
| -18% | -$263K | 0.02% | 286 |
|
|
2025
Q1 | $1.52M | Buy |
16,947
+660
| +4% | +$59.1K | 0.03% | 223 |
|
|
2024
Q4 | $1.3M | Buy |
16,287
+3,215
| +25% | +$278K | 0.02% | 240 |
|
|
2024
Q3 | $1.18M | Sell |
13,072
-1,483
| -10% | -$125K | 0.02% | 250 |
|
|
2024
Q2 | $1.15M | Buy |
14,555
+786
| +6% | +$64.4K | 0.02% | 235 |
|
|
2024
Q1 | $1.2M | Buy |
13,769
+2,799
| +26% | +$239K | 0.02% | 212 |
|
|
2023
Q4 | $904K | Sell |
10,970
-3,505
| -24% | -$267K | 0.02% | 243 |
|
|
2023
Q3 | $1.13M | Sell |
14,475
-353
| -2% | -$29.6K | 0.03% | 186 |
|
|
2023
Q2 | $1.31M | Buy |
14,828
+944
| +7% | +$81.3K | 0.03% | 167 |
|
|
2023
Q1 | $1.12M | Buy |
13,884
+5,703
| +70% | +$465K | 0.03% | 183 |
|
|
2022
Q4 | $636K | Sell |
8,181
-3,568
| -30% | -$289K | 0.02% | 238 |
|
|
2022
Q3 | $948K | Buy |
11,749
+1,452
| +14% | +$130K | 0.03% | 165 |
|
|
2022
Q2 | $925K | Sell |
10,297
-2,651
| -20% | -$269K | 0.03% | 160 |
|
|
2022
Q1 | $1.44M | Buy |
12,948
+2,933
| +29% | +$310K | 0.05% | 135 |
|
|
2021
Q4 | $1.03M | Buy |
10,015
+1,234
| +14% | +$143K | 0.03% | 173 |
|
|
2021
Q3 | $1.1M | Sell |
8,781
-148
| -2% | -$19.2K | 0.04% | 152 |
|
|
2021
Q2 | $1.11M | Sell |
8,929
-190
| -2% | -$23.9K | 0.04% | 145 |
|
|
2021
Q1 | $1.08M | Buy |
9,119
+1,851
| +25% | +$217K | 0.04% | 144 |
|
|
2020
Q4 | $850K | Sell |
7,268
-404
| -5% | -$44.5K | 0.03% | 157 |
|
|
2020
Q3 | $798K | Buy |
7,672
+276
| +4% | +$27.7K | 0.04% | 158 |
|
|
2020
Q2 | $678K | Buy |
7,396
+413
| +6% | +$39.6K | 0.03% | 179 |
|
|
2020
Q1 | $629K | Buy |
6,983
+694
| +11% | +$73.8K | 0.04% | 166 |
|
|
2019
Q4 | $714K | Buy |
6,289
+126
| +2% | +$13.8K | 0.03% | 187 |
|
|
2019
Q3 | $670K | Buy |
6,163
+546
| +10% | +$57K | 0.03% | 185 |
|
|
2019
Q2 | $547K | Buy |
5,617
+1,383
| +33% | +$126K | 0.03% | 205 |
|
|
2019
Q1 | $385K | Sell |
4,234
-3,894
| -48% | -$349K | 0.02% | 215 |
|
|
2018
Q4 | $739K | Buy |
8,128
+3,913
| +93% | +$366K | 0.04% | 150 |
|
|
2018
Q3 | $414K | Sell |
4,215
-136
| -3% | -$12.6K | 0.02% | 221 |
|
|
2018
Q2 | $372K | Sell |
4,351
-96
| -2% | -$8.02K | 0.02% | 225 |
|
|
2018
Q1 | $356K | Sell |
4,447
-298
| -6% | -$24.6K | 0.02% | 238 |
|
|
2017
Q4 | $384K | Sell |
4,745
-3,494
| -42% | -$280K | 0.02% | 227 |
|
|
2017
Q3 | $641K | Buy |
8,239
+2,065
| +33% | +$171K | 0.04% | 165 |
|
|
2017
Q2 | $524K | Buy |
6,174
+2,153
| +54% | +$182K | 0.04% | 195 |
|
|
2017
Q1 | $325K | Buy |
+4,021
| New | +$314K | 0.02% | 168 |
|
|
2016
Q4 | – | Sell |
-3,897
| Closed | -$337K | – | 220 |
|
|
2016
Q3 | $337K | Sell |
3,897
-516
| -12% | -$45K | 0.03% | 131 |
|
|
2016
Q2 | $383K | Buy |
4,413
+360
| +9% | +$29.1K | 0.03% | 134 |
|
|
2016
Q1 | $304K | Buy |
+4,053
| New | +$305K | 0.03% | 156 |
|
|
2015
Q3 | – | Sell |
-2,922
| Closed | -$217K | – | 161 |
|
|
2015
Q2 | $217K | Sell |
2,922
-356
| -11% | -$27.2K | 0.02% | 151 |
|
|
2015
Q1 | $256K | Buy |
3,278
+307
| +10% | +$23.3K | 0.03% | 135 |
|
|
2014
Q4 | $215K | Buy |
+2,971
| New | +$206K | 0.02% | 144 |
|
Other funds holding MDT
Ballentine Partners's MDT Position: Q2 2026 in Review
Ballentine Partners reduced its Medtronic (MDT) stake by 27% in Q2 2026, selling an estimated $402K and leaving 13,573 shares worth $1.06M. The position accounts for 0.01% of the portfolio, ranked #356.
Ballentine Partners first reported a position in MDT in Q4 2014 and has held it in 44 quarters since. The position peaked at $1.61M in Q1 2026. 2,128 funds tracked by Wall St. Rank hold MDT as of Q2 2026.
- Ballentine Partners held 13,573 shares of Medtronic worth $1.06M as of Q2 2026.
- Ballentine Partners sold 4,983 Medtronic shares in Q2 2026, an estimated $402K.
- Medtronic made up 0.01% of Ballentine Partners's portfolio in Q2 2026, its #356 holding.
- Ballentine Partners first reported a position in Medtronic in Q4 2014 and has held it in 44 quarters since.
- Ballentine Partners's Medtronic position peaked at $1.61M in Q1 2026.
- 2,128 funds tracked by Wall St. Rank held Medtronic as of Q2 2026.
Based on Ballentine Partners's 13F filing for Q2 2026, filed 17 Jul 2026.